Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.31
+0.56002.26%
Volume:28.08K
Turnover:711.17K
Market Cap:696.05M
PE:-9.41
High:25.64
Open:25.17
Low:25.00
Close:24.75
Loading ...

Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Dow Jones
·
18 hours ago

Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Dow Jones
·
18 hours ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

GlobeNewswire
·
18 hours ago

Allogene Therapeutics Q4 EPS $(0.28) Beats $(0.33) Estimate

Benzinga
·
18 hours ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire
·
18 hours ago

Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
22 hours ago

Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction

TIPRANKS
·
Yesterday

Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects

TIPRANKS
·
Yesterday

Buy Rating for Contineum Therapeutics: Promising Pipeline and Market Opportunities

TIPRANKS
·
Yesterday

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge

MT Newswires Live
·
Yesterday

Transcode Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures

MT Newswires Live
·
Yesterday

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
Yesterday

Assertio Therapeutics (ASRT) Gets a Buy from Lake Street

TIPRANKS
·
Yesterday

JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target

MT Newswires Live
·
Yesterday

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice

MT Newswires Live
·
Yesterday